ArticleThe journal of obstetrics and gynaecology research2026
Prognostic Impact of WHO 2020 Lymphovascular Space Invasion Categories in Endometrial Cancer: Substantial LVSI as an Independent Risk Factor and the Behavior of LVSI-Positive, Node-Negative Disease.
Article in The journal of obstetrics and gynaecology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the prognostic significance of lymphovascular space invasion (LVSI), classified according to the 2020 World Health Organization (WHO) criteria, on disease-free survival (DFS) and overall survival (OS) in endometrial cancer, and to characterize the prognosis of LVSI-positive, lymph node-negative disease.
methodsThis retrospective single-center cohort study included 568 patients with endometrial carcinoma who underwent primary surgical treatment with comprehensive surgical staging, including lymph node assessment, between January 2023 and December 2025. LVSI was classified as absent, focal, or substantial. Survival outcomes were estimated by the Kaplan-Meier method and compared by log-rank test. Independent predictors of DFS and OS were identified by multivariable Cox proportional hazards regression. A four-group analysis combining LVSI and lymph node status was also performed.
resultsLVSI was absent in 413 patients (72.7%), focal in 39 (6.9%), and substantial in 116 (20.4%). Median follow-up was 20.0 months. On multivariable analysis, substantial LVSI was an independent predictor of reduced DFS (HR 2.22, 95% CI: 1.14-4.32; p = 0.018) and OS (HR 3.48, 95% CI: 1.34-9.00; p = 0.010), whereas focal LVSI did not retain independent prognostic significance. LVSI-positive/lymph node-negative patients had significantly worse DFS than LVSI-negative/lymph node-negative patients (p < 0.001) and did not differ significantly from LVSI-negative/lymph node-positive patients (p = 0.065), suggesting recurrence outcomes approaching those of node-positive disease.
conclusionSubstantial LVSI is an independent adverse prognostic factor in endometrial cancer. LVSI-positive/lymph node-negative patients demonstrated recurrence outcomes approaching those of lymph node-positive disease; given the limited follow-up, this finding is hypothesis-generating and requires prospective validation before informing treatment escalation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.